Objective  This study aimed to investigate the expression of CysLT1R and CysLT2R mRNA in breast cancer tissues, and to explore its relationship with clinicopathological features and prognosis.

  Methods  Breast cancer and normal para-neoplastic tissues were obtained from 90 and 30 patients, respectively. The expression of CysLT1R and CysLT2R mRNA was determined by real-time polymerase chain reaction. The relationships of this expression with clinicopathological features and prognosis were analyzed.

  Results  CysLT1R gene expression was significantly higher in breast cancer tissues than in para-neoplastic tissues. CysLT2R gene expression was significantly lower in breast cancer tissues than in the adjacent non-cancerous tissues (P < 0.01). The tumor size, histological type, lymph node metastasis, and TNM staging expression were positively correlated with the CysLT1R expression in breast cancer (P < 0.05). However, these clinical factors were negatively correlated with CysLT2R expression (P < 0.05). Kaplan–Meier survival analysis showed that patients with elevated CysLT1R expression in breast cancer exhibited poor prognosis (P < 0.05), whereas patients with elevated CysLT2R expression in breast cancer showed good prognosis (P < 0.05).

  Conclusion  CysLT1R and CysLT2R may be new molecular markers for the prognosis of breast cancer patients.